Literature DB >> 9663219

Excimer laser treatment of myopic astigmatism. A comparison of three ablation programs.

J Colin1, B Cochener, G Le Floch.   

Abstract

OBJECTIVE: The purpose of the study was to evaluate the precision, accuracy, and safety of three different modes of excimer laser surgery for myopic astigmatism.
DESIGN: A prospective interventional case series. PARTICIPANTS: A total of 150 eyes with compound myopic astigmatism were treated. INTERVENTION: Ablation programs included the VISX Twenty/Twenty excimer laser using either the sequential mode (58 eyes) or the elliptical mode (54 eyes) and the Technolas-Chiron Keracor 116 hybrid scanning laser (38 eyes). MAIN OUTCOME MEASURES: Reduction in cylinder and sphere, vector analysis (polar values), uncorrected visual acuity, and best spectacle-corrected visual acuity were evaluated at 1, 6, and 12 months.
RESULTS: By 12 months, sphere was reduced by 95.1%, 87.7%, and 75% in low-astigmatism eyes treated with the VISX sequential, VISX elliptical, and Technolas modes, respectively, and by 92.2%, 98%, and 77.6% in high-astigmatism eyes. By 12 months, cylinder was reduced by 51.5%, 72.2%, and 36.3% in low-astigmatism eyes and by 70%, 78%, and 45.6%, respectively, in high-astigmatism eyes. Vector analysis showed that the elliptical treatment produced more significant reductions in mean polar values than the other two treatments at various timepoints.
CONCLUSION: These results suggest that the ablation approach may influence the clinical result.

Entities:  

Mesh:

Year:  1998        PMID: 9663219     DOI: 10.1016/S0161-6420(98)97017-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  1 in total

1.  Comparison between Wavefront-optimized and corneal Wavefront-guided Transepithelial photorefractive keratectomy in moderate to high astigmatism.

Authors:  Ikhyun Jun; David Sung Yong Kang; Samuel Arba-Mosquera; Jin Young Choi; Hyung Keun Lee; Eung Kweon Kim; Kyoung Yul Seo; Tae-Im Kim
Journal:  BMC Ophthalmol       Date:  2018-06-26       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.